Aclaris Therapeutics, Inc.
NASDAQ:ACRSBiotechnology
+$0.03 today
- Market cap
- $555.14M
- Beta
- 0.80
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$0.54
Volume 2.94M
Average 1.40M
ACRS Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Aclaris Therapeutics, Inc.NASDAQ: ACRS
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin growth accelerates
Q1 FY2026 selling, general & admin of $6.74M rose 9.8% year over year, ahead of the +5.5% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 20.9% from the prior quarter. Over 3 fiscal years it compounded at -4.4% a year.
Context
- Selling, general & admin amounted to 280.8% of revenue in FY2025, up 162.2 pp from a year earlier.
- Selling, general & admin increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 7 analysts of $11.89M (-45.9%) for the fiscal year ending Dec 2026, a slowdown from the -1.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $6.74M+20.9% QoQ
- Last fiscal yearDec 2025
- $21.97M-1.0% YoY
- LTMMar 2026
- $22.58M+5.5% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 21.97M USD
- Year-over-year change
- -1.0%
- 4-year CAGR
- -1.8%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 21.97M | -1.0% |
| FY2024 | 2024-12-31 | 22.2M | -28.6% |
| FY2023 | 2023-12-31 | 31.1M | +23.7% |
| FY2022 | 2022-12-31 | 25.13M | +6.4% |
| FY2021 | 2021-12-31 | 23.62M | — |
Selling, General & Admin vs competitors
How ACRS compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +5.5% is the 9th highest of 10, against a peer median of +37.0%.
- Selling, general & admin amounts to 269.8% of revenue for ACRS, versus a peer median of 1022.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.14T USD | +9732467.6% | -14.5% | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $77.08M USD | +17.2% | +94.2% | 1041.9% |
| LTM Mar 2026 | $62.81M USD | +42.2% | +11.5% | 27.0% | |
| LTM Mar 2026 | $46.46M USD | +34.5% | +22.2% | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | $39.39M USD | +37.0% | — | — |
| LTM Mar 2026 | $23.53M USD | +30.1% | +11.7% | — | |
| LTM Mar 2026 | $22.58M USD | +5.5% | -4.4% | 269.8% | |
| LTM Mar 2026 | €14.24M EUR | -27.6% | +7.0% | 48538.7% | |
| FY2025 | $13.55M USD | +83.7% | — | 1003.9% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | €9.82M EUR | +63.8% | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ACRS) | — | +37.0% | +11.6% | 1022.9% | |
Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.76M | 29.75M | 31.25M | 18.72M | 7.83M |
| Cost of Revenue | 4.71M | 11.96M | 18.08M | 2.79M | 2.09M |
| Gross Profit | 2.05M | 17.79M | 13.17M | 15.93M | 5.74M |
| Gross Margin | 30.3% | 59.8% | 42.1% | 85.1% | 73.3% |
| Research & Development | 43.81M | 77.81M | 98.38M | 33.59M | 52.65M |
| Selling, General & Admin | 23.62M | 25.13M | 31.1M | 22.2M | 21.97M |
| Operating Expenses | 91.77M | 107.65M | 110.53M | 157.86M | 82.11M |
| Depreciation & Amortization | 923K | 797K | 863K | 807K | 454K |
| EBITDA | (64.46M) | (84.36M) | (115.45M) | (51.72M) | (64.47M) |
| EBITDA Margin | -953.4% | -283.5% | -369.5% | -276.3% | -823.8% |
| Operating Income | (89.72M) | (89.85M) | (97.36M) | (141.93M) | (76.38M) |
| Operating Margin | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% |
| Interest Income | 0 | 0 | 0 | 7.95M | 7.64M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.14M) | 2.95M | 8.51M | 9.87M | 11.45M |
| Income Before Tax | (90.87M) | (86.91M) | (88.85M) | (132.07M) | (64.92M) |
| Pre-Tax Margin | -1344.0% | -292.1% | -284.3% | -705.5% | -829.6% |
| Income Tax Expense | 0 | 0 | (367K) | 0 | 0 |
| Net Income | (90.87M) | (86.91M) | (88.48M) | (132.07M) | (64.92M) |
| Net Margin | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% |
| EPS (Basic) | (1.60) | (1.33) | (1.27) | (1.71) | (0.53) |
| EPS (Diluted) | (1.60) | (1.33) | (1.27) | (1.71) | (0.53) |
| Weighted Avg Shares | 56.73M | 65.21M | 69.81M | 77.3M | 122.66M |
| Weighted Avg Shares (Diluted) | 56.73M | 65.21M | 69.81M | 77.3M | 122.66M |
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.